Former Chief Executive Officer · Xeris Biopharma Holdings, Inc. (XERS)

Paul Edick

A named executive officer of Xeris Biopharma in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$6,826,608

Salary $421,449Stock awards $3,690,000

FY2023: $2,136,766

1st of 6 named executive officers at Xeris Biopharma by FY2024 total.

6 named officers on file for Xeris Biopharma, FY2024

Paul Edick’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • XERS’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Xeris Biopharma’s whole pay program stands against its peers

  • Xeris Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XERS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2025 (DEF 14A).

Free

Get Paul Edick’s full pay file as a PDF — free

More than this page: up to 10 years of Paul’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Paul Edick compensation by year

Xeris Biopharma Summary Compensation Table · all 5 fiscal years held
In US dollars, as Xeris Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024
Salary$626,977$664,096$691,710$693,934$421,449
Bonus$0$0$0$0$0
Stock awards$1,178,450$1,143,000$1,686,000$930,000$3,690,000
Option awards$0$1,352,720$0$0$538,969
Non-equity incentive$453,222$598,518$416,360$499,632$301,123
Pension and deferred compensation$0$0$0$0$0
All other$5,700$5,800$11,529$13,200$1,875,067
Total$2,264,349$3,764,134$2,805,599$2,136,766$6,826,608

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xeris Biopharma Holdings, Inc. DEF 14A filed April 23, 2025, accession 0001867096-25-000068, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Xeris Biopharma Holdings, Inc. filed document, accession 0001867096-25-000068. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2025.

$2.3M
$3.8M
$2.8M
$2.1M
$6.8M
FY20
FY21
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU1,500,000$5,085,000—
RSU200,000$678,000—
Option8,334—$5.08
Option500,000—$2.46

Per the Outstanding Equity Awards at Fiscal Year-End table in Xeris Biopharma Holdings, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Xeris Biopharma’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Paul Edick · this pageFormer Chief Executive Officer$6,826,608
John ShannonChief Executive Officer$3,827,109
Beth HechtChief Legal Officer and Corporate Secretary$2,612,825
Kevin McCullochPresident and Chief Operating Officer$2,577,572
Steven PieperChief Financial Officer$1,854,017
Ken JohnsonSenior Vice President, Global Development and Medical Affairs$1,058,429

Board service

Xeris Biopharma board · FY2021–FY2022

How this board is paid

Company policy: Xeris Biopharma pays directors a $40,000 cash retainer. As stated in Xeris Biopharma's FY2022 proxy.

The full Xeris Biopharma compensation record

free company brief

This page is one person within Xeris Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xeris Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Paul Edick's compensation dossier · One-time report. No refunds.